Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Enterin Inc. logo — Improving the quality of life of patients with neurodegenera...

Enterin Inc.

Improving the quality of life of patients with neurodegenerative conditions by repairing the gut-brain axis.

Founded 2016 United States Philadelphia, United States 18 employees Venture round Total: $81.60M Biopharma, Biotechnology

General Information

Company Name Enterin Inc.
Founded Year 2016
Location United States Philadelphia, United States
Employees 18
Industries Biopharma, Biotechnology
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Enterin Inc.. To contact Enterin Inc., visit enterininc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Enterin Inc. compare?

A PDF of Enterin Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Enterin Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Enterin Inc.

Enterin Inc. is a biopharmaceutical company focused on improving the quality of life for patients with neurodegenerative conditions. By repairing the dysfunctional gut-brain axis, Enterin aims to pioneer the understanding of the link between infections, dysfunction of the enteric nervous system (ENS), and the onset and progression of neurodegenerative diseases. Their lead compound, ENT-01, has shown promising results in preclinical models of Parkinson’s disease by displacing membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS, thus improving neural signaling between the gut and the brain. With a $5.10M Venture Round investment received on 06 December 2023, Enterin Inc. is advancing their clinical trials to reverse the constipation associated with Parkinson’s disease. As a company founded in 2016 and based in the United States, Enterin Inc. aims to become a world leader in developing pharmaceutical therapies to enhance the quality of life for patients with neurodegenerative conditions.

Business keywords: Neurodegenerative disease, Biopharmaceutical company, Parkinson's Disease, Clinical stage, Gut-brain axis, Enteric nervous system, Alpha-synuclein, Neurological disorders, Clinical trials, Synthetic derivatives, Endogenous hormones, Misfolded proteins, Quality of life, Medical community, Drug development

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $5.10M -
06 Dec 2023
Convertible Note $6.00M 1
Voloridge Investment Management, LLC
Voloridge Investment Management, LLC
03 Oct 2022
Convertible Note $19.10M -
23 Mar 2021
Series C $14.20M -
14 Sep 2020
Series B $20.40M 1
New Ventures III
01 Feb 2019
Series A $16.80M 1
New Ventures III
15 Jul 2017

Enterin Inc. Alternatives & Competitors

View All Alternatives
Enterin Inc. vs
Bloom Science, Inc.
Bloom Science, Inc. United States

Leveraging the Gut-Brain Axis to Drive Therapeutic Innovation

Series A
17 employees
Biopharma, Biotechnology
Enterin Inc. vs
Vertero Therapeutics, Inc.
Vertero Therapeutics, Inc. United States

Pioneering science beyond the brain to treat neurodegenerative diseases at their source

Series C
12 employees
Biopharma, Biotechnology
Enterin Inc. vs
Neurolixis
Neurolixis United States

New treatments for central nervous system disorders

Seed
5 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Enterin Inc.

Improving the quality of life of patients with neurodegenerative conditions by repairing the gut-brain axis.
Enterin Inc. was founded in 2016.
Enterin Inc. is headquartered in Philadelphia, United States.
Enterin Inc. operates in Biopharma and Biotechnology. Its work centres on Neurodegenerative disease, Biopharmaceutical company, Parkinson's Disease and Clinical stage.
Enterin Inc. has approximately 18 employees.
Enterin Inc. has completed 6 funding rounds, raising a total of $81.60M. The latest funding stage is Venture round.
Top alternatives and competitors to Enterin Inc. include Bloom Science, Inc., Vertero Therapeutics, Inc., Neurolixis, Raptor Pharmaceuticals, Minerva Neurosciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Enterin Inc. and Bloom Science, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Enterin Inc., https://bouncewatch.com/company/enterin-inc, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes